Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
Jaguar Health announced the approval of all proposals at its Annual Meeting of Stockholders held on June 21, 2024. Five proposals were submitted and approved, details of which are available in the company's proxy statement filed with the SEC. Jaguar will report results from its pivotal phase 3 OnTarget trial for the cancer supportive care drug crofelemer by July 23, 2024. An investor webcast on or before this date will include updates on Jaguar's cancer supportive care portfolio, featuring insights from the scientific team, patient advocates, and oncology experts. In celebration of World Rainforest Day on June 22, Jaguar shared a RealPharma podcast interview with Dr. Steven King, highlighting his ethnobotanical research and the medicinal use of plants by indigenous Amazonian communities.
- All proposals submitted at the Annual Meeting were approved by stockholders.
- Pivotal phase 3 OnTarget trial results for crofelemer will be reported by July 23, 2024.
- Investor webcast will provide updates on Jaguar's cancer supportive care portfolio.
- None.
Insights
Jaguar Health's announcement regarding the pivotal phase 3 OnTarget trial results for its cancer supportive care drug, crofelemer, is a significant milestone. Crofelemer is being studied for the treatment of cancer therapy-related diarrhea, a common and debilitating side effect of cancer treatments. The upcoming results, expected by July 23, 2024, are particularly important for patients and healthcare providers seeking effective supportive care options.
Understanding the potential efficacy and safety of crofelemer in this context will be crucial. If the trial results are positive, it could enhance crofelemer's market potential and offer a new therapeutic option that addresses a significant unmet need. However, investors should be aware of the inherent risks associated with clinical trials. There's always a possibility that the results may not meet the desired endpoints, which could negatively impact the stock price.
The FDA's future involvement will also be a critical factor. Positive results could lead to regulatory approval, while negative outcomes might necessitate further trials or adjustments in study design. Investors should closely monitor updates from the webcast and the company's communications for detailed insights into the trial data and next steps.
The upcoming release of pivotal phase 3 trial results for crofelemer is likely to have a substantial impact on Jaguar Health's stock. Phase 3 trials are typically the final step before a new drug can be considered for approval by regulatory bodies. Consequently, investors will be looking closely at the efficacy data and any potential financial implications.
If the results are favorable, this could lead to a surge in stock price as market confidence in the drug's approval and subsequent revenue potential increases. Additionally, a successful phase 3 trial often attracts partnerships and licensing opportunities, which can provide non-dilutive financing and further enhance the company’s liquidity.
However, it's important to consider the financial risks. Negative or inconclusive results could lead to a decline in stock value and may require the company to raise additional capital, potentially through dilutive equity offerings. Investors should remain cautious and consider the company's existing financial health and funding strategy in the event of an unfavorable outcome.
Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024
Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea and oral mucositis
In honor of World Rainforest Day (June 22), Jaguar is proud to share RealPharma podcast interview with ethnobotanist Dr. Steven King
SAN FRANCISCO, CA / ACCESSWIRE / June 21, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Annual Meeting of Stockholders held June 21, 2024 (the "Annual Meeting").
Five proposals were submitted to and approved by the stockholders of the Company at the Annual Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Annual Meeting on May 21, 2024 and supplemental information filed with the Securities and Exchange Commission. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at http://www.sec.gov. The proxy statement is also available on the Company's corporate website.
"In honor of World Rainforest Day (June 22), we are proud to share the link to RealPharma's recent podcast interview with ethnobotanist Steven King, PhD, Jaguar's Chief Sustainable Supply, Ethnobotanical Research, and IP Officer," said Lisa Conte, the Company's founder, president and CEO. "The RealPharma podcast series is hosted by Dr. Na-Ri Oh and Ian Wendt, Jaguar's Chief Commercial Officer. In the interview, Dr. King shares incredible stories from his journey - like living with indigenous communities in the Amazon and learning about their medicinal uses of plants. He also discusses the powerful impact these natural resources can have on global health, all while preserving the cultures that discovered them. It's a testament to how ancient wisdom and cutting-edge science can work hand-in-hand. The podcast episode can be accessed at this link: From the Forest to your Pharmacy: Dr. Steven King's Ethnobotanical Journey."
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Crofelemer also is the subject of Napo's phase 3 OnTarget clinical trial for preventive treatment of cancer therapy-related diarrhea (CTD). Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program at makecancerlessshitty.com and on X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Jaguar will provide the results of the OnTarget trial and updates on the Company's cancer supportive care portfolio on or before July 23, 2024, and the expectation that Jaguar will hold an investor webcast on or before July 23, 2024. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on accesswire.com
FAQ
What proposals were approved at Jaguar Health's 2024 Annual Meeting?
When will Jaguar Health report the phase 3 OnTarget trial results for crofelemer?
What updates will be discussed in Jaguar Health's investor webcast?
How is Jaguar Health celebrating World Rainforest Day?
